Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
Health and Human Services (all) · BARDA - ASPR / DAAPPO / BARDA DCMA
No listed company matched (Materiality N/A)
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75A50126C00006 in this department, oldest first.
- Jun 5, 2026 · this noticeAward NoticeFlosonics Medical LLC · $99.7M
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Note the winner and the end of the period of performance for the recompete.
- Follow the agency to see the next notice for this work.
What the notice says
The Pandemic and All Hazards Preparedness Act (PAHPA) of 2006 established the Center for the Biomedical Advanced Research and Development Authority (BARDA) and was reauthorized under the PAHPA of 2013 and again in 2019 under the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAIA), Public Law No. 116-22, to support development and acquisition of medical countermeasure (MCMs) to prevent or treat the medical consequences of chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza (PI), and emerging infectious diseases (EID). These MCMs include va… (show all)
ccines, therapeutics, diagnostics, and medical devices. Additionally, BARDA is entrusted to foster innovation of technologies that enable better manufacturing, testing, and utilization of these medical countermeasures. The overall objective of this contract is to advance the development of FloPatch FP120 with FloPredict Alert for Burn and Blast Medical Countermeasure. The scope of work for this contract includes clinical and product development activities that fall into the following areas: clinical studies, algorithms, hardware and software development, and all associated regulatory, quality assurance, management, and administrative activities. The Government has determined a Bona Fide Need for each non-severable discrete work segment which will conclude upon the completion of a defined tasks that provide(s) independent merit and value to the Government. The Contractor's success in completing the required tasks under the work segments must be demonstrated through the Deliverables and Milestones specified under Article F of this contract. As set forth in Attachment 1, Statement of Work, the Go/No-Go, Deliverable, and/or Milestone will constitute the basis for the Government�s decision, at its sole discretion, to exercise any follow-on option period(s).
Who won similar work
4 award notices on SAM.gov in the last 24 months. Matched by: Same office (BARDA - ASPR / DAAPPO / BARDA DCMA), same product/service code (PSC) AN13 and NAICS 541714.
Single-winner award sizes (4): middle half $75.8M to $224.3M, median $142.3M; range $7.5M to $339.2M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| CIDARA THERAPEUTICS INC | 1 | $339.2M | Oct 14, 2025 |
| RAFA LABORATORIES LTD | 1 | $186.0M | Oct 1, 2025 |
| OSIVAX Paris 8 �le-de-France 75008 FRA | 1 | $98.6M | Oct 14, 2025 |
| ISOLA THERAPEUTICS INC | 1 | $7.5M | Apr 27, 2026 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- Apr 27, 2026ISOLA THERAPEUTICS INC$7.5MBARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)No listed company matched (Materiality N/A)
- Oct 14, 2025OSIVAX Paris 8 �le-de-France 75008 FRA$98.6MClinical Proof of Concept of OVX836, a single-shot broadly protective Influenza A vaccine for immediate protection against emerging pandemic strainsNo listed company matched (Materiality N/A)
- Oct 14, 2025CIDARA THERAPEUTICS INC$339.2MDevelopment of CD388 as a long-lasting prophylactic anti-viral option for protection against the health impacts caused by influenzaNo listed company matched (Materiality N/A)
- Oct 1, 2025RAFA LABORATORIES LTD$186.0MDevelopment Of a Concentrated Tranexamic Acid (TXA) Intramuscular InjectionNo listed company matched (Materiality N/A)
Competitive landscape
For the 4 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Health & Human Services, Dept of (HHS) since 2024 (3 filings)
- 0 of their lobbyists list a past Health & Human Services, Dept of (HHS) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 253 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.